Connect with us

Hi, what are you looking for?

Jewish Business News

Business

3D Systems to Acquire Israeli Simbionix for $120 million in Cash


Simbonix develops 3D virtual reality simulation systems to train doctors in complex surgical and treatment procedures.

images

 

3D Systems (NYSE:DDD) (3DS) has agreed to acquire Simbionix for $120 million in cash. Simbionix has developed 3D virtual reality simulation systems for training doctors to conduct complex surgical and treatment procedures. The transaction is expected to be completed within the next 30 days, subject to customary closing conditions.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.

Simbonix was founded in 1997 by CEO of the company, Gary Zamler, COO and President Ran Bronstein, and CFO Boaz Tal. The company raised $14 million, $7 million  raised in the last major financing round in 2008. Investors include Early Stage Partners, Koor, Etrinsic, Rad Biomed, and  Israel-United States Binational Industrial Research and Development Foundation (BIRD-F) and the Office of the Israel Chief Scientist.

US-based 3D Systems offers a range of 3D printing systems in various areas including medicine and the company therefore sees the acquisition as synergy driven.

 

3D Systems to Acquire Simbionix

3DS CEO Avi Reichental said, “Simbionix is a perfect match for our healthcare business and its powerful technology, products, channels and domain expertise expands our 3D healthcare capabilities from the training room to the operating room, and extends our first mover advantage in this fast growing vertical.”

Headquartered in Cleveland, Ohio with an R&D center in Israel’s Airport City, Simbionix has pioneered patient-specific simulation with FDA-cleared solutions that are changing the way preparation for individual surgeries are carried out. Its proprietary simulation and training products are revolutionizing the way physicians practice and master surgical procedures with improved learning that can favorably impact patient outcomes.

Simbionix has dozens of employees and annual revenue of tens of millions of dollars. The company is probably profitable because 3DS says that the acquisition will contribute to its cash flow and profitability.

The company plans to operate Simbionix under the continued leadership of Gary Zamler, CEO of Simbionix, who will become Vice President and General Manager of Simbionix Products.

 

Newsletter



Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

Entertainment

The Movie The Professional is what made Natalie Portman a Lolita.

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.